Identifying an optimal cutpoint for the diagnosis of hypertriglyceridemia in the nonfasting state

Clinical Chemistry

Volumn 61, Issue 9, 2015, Pages 1156-1163

  White, Khendi T ^a   Moorthy, M V ^a   Akinkuolie, Akintunde O ^a   Demler, Olga ^a   Ridker, Paul M ^a,b   Cook, Nancy R ^a,b   Mora, Samia ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; BOOTSTRAPPING; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONFIDENCE INTERVAL; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HAZARD RATIO; HORMONAL THERAPY; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LOGISTIC REGRESSION ANALYSIS; MENOPAUSE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE VALUE; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SMOKING; YOUDEN INDEX; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; DIET RESTRICTION; MIDDLE AGED; POSTPRANDIAL STATE; RECEIVER OPERATING CHARACTERISTIC;

CARDIOVASCULAR DISEASES; FASTING; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; MIDDLE AGED; POSTPRANDIAL PERIOD; ROC CURVE; TRIGLYCERIDES;

EID: 84942549171     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2015.241752     Document Type: Article

References (40)

1. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet 2014;384:626-35.
2. Shai I, Rimm EB, Hankinson SE, Cannuscio C, Curhan G, Manson JE, Rifai N, Stampfer MJ, Ma J. Lipoprotein(a) and coronary heart disease among women: beyond a cholesterol carrier? Eur Heart J. 2005;26:1633-9.
3. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005;294:326-33.
4. Alipour A, van Oostrom AJHHM, Izraeljan A, Verseyden C, Collins JM, Frayn KN, Plokker TWM, Elte JWF, Castro Cabezas M. Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol 2008;28:792-7.
5. Wang L, Gill R, Pedersen TL, Higgins LJ, Newman JW, Rutledge JC. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J Lipid Res 2009;50:204-13.
6. Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol 1995;15:534-42.
7. Steiner G, Schwartz L, Shumak S, Poapst M. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease. Circulation 1987;75:124-30.
8. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, et al. American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism, Council on Arteriosclerosis, Thrombosis, and Vascular Biology, Council on Cardiovascular Nursing, Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011;123:2292-333.
9. Sniderman AD. Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is. Circulation 2005;112:3366-7.
10. McBride PE. Triglycerides and risk for coronary heart disease. JAMA 2007;298:336-8.
11. Kolovou GD, Mikhailidis DP, Kovar J, Lairon D, Nordestgaard BG, Ooi TC, Perez-Martinez P, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011;9:258-70.
12. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298:309-16.
13. Nordestgaard BG, Benn M, Schnohr P, Tybaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease and death in men and women. JAMA 2007;298:299-308.
14. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008;118:993-1001.
15. Eberly LE, Stamler J, Neaton JD, Multiple Risk Factor Intervention Trial Research Group. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 2003;163:1077-83.
16. Stensvold I, Tverdal A, Urdal P, Graff-Iversen S. Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women. BMJ 1993;307:1318-22.
17. Langsted A, Freiberg JJ, Tybjaerg-Hansen A, Schnohr P, Jensen GB, Nordestgaard BG. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med 2011;270:65-75.
18. Stalenhoef AFH, de Graaf J. Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL. Curr Opin Lipidol 2008;19:355-61.
19. Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, Gustafsson S, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 2013;45:1345-52.
20. Rosenson RS, Davidson MH, Hirsh BJ, Kathiresan S, Gaudet D. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. J Am Coll Cardiol 2014;64:2525-40.
21. Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013;61:427-36.
22. Thomsen M, Varbo A, Tybjaerg-Hansen A, Nordestgaard BG. Low nonfasting triglycerides and reduced allcause mortality: a Mendelian randomization study. Clin Chem 2014;60:737-46.
23. Jorgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjaerg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 2013;34:1826-33.
24. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106:3143-421.
25. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2889-934.
26. Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GB, McPherson R, Francis GA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013;29:151-67.
27. European Association for Cardiovascular Prevention and Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, et al. ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818.
28. Hegele RA, Ginsberg HN, Chapman JM, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrin 2013;13:70191-8.
29. Lima-Oliveira G, Salvagno GL, Lippi G, Gelati M, Montagnana M, Danese E, Picheth G, Guidi GC. Influence of a regular, standardized meal on clinical chemistry analytes. Ann Lab Med 2012;32:250-6.
30. Cook NR, Lee IM, Gaziano JM. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:47-55.
31. Green MS, Symons MJ. A comparison of the logistic risk function and the proportional hazards model in prospective epidemiologic studies. J Chronic Dis 1983;36:715-23.
32. Pepe MS. The statistical evaluation of medical tests for classification and prediction. Oxford, UK: Oxford University Press; 2004.
33. Goldberg IJ, Eckel RH, McPherson R. Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol 2011;31:1716-25.
34. Stone B, J. Cross-validatory choice and assessment of statistical predictions. Stat Soc 1974;36:111-47.
35. Efron DT, Barbul A. Modulation of inflammation and immunity by arginine supplements. Curr Opin Clin Nutr Metab Care 1998;1:531-8.
36. Hastie T, Friedman J, Tibshirani R. The elements of statistical learning. New York: Springer; 2009.
37. Saraswathi V, Hasty AH. The role of lipolysis in mediating the proinflammatory effects of very low density lipoproteins in mouse peritoneal macrophages. J Lipid Res 2006;47:1406-15.
38. Gupta M, Singh N, Tsigoulis M, Kajil M, Hirjikaka S, Quan A, Teoh H, Verma S. Perceptions of Canadian primary care physicians towards cardiovascular risk assessment and lipid management. Can J Cardiol 2012;28:14-9.
39. Doran B, Guo Y, Xu J, Weintraub H, Mora S, Maron DJ, Bangalore S. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). Circulation 2014;130:546-53.
40. Nordestgaard BG, Langsted A, Freiberg JJ. Nonfasting hyperlipidemia and cardiovascular disease. Curr Drug Targets 2009;10:328-35.